Lumacaftor and Ivacaftor

Brand names: Orkambi · Active ingredient: Lumacaftor, Ivacaftor

In short: ORKAMBI is indicated for the treatment of cystic fibrosis (CF) in patients aged 1 year and older who are homozygous for the F508del mutation in the CFTR gene. If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the F508del mutation on both a

Forms & strengthsTablets: 100 mg lumacaftor and 125 mg ivacaftor; supplied as pink, oval-shaped, film-coated, fixed-dose combination tablets containing 100 mg of lumacaftor and 125 mg of ivacaftor. …
LabelVertex Pharmaceuticals Incorporated
Label updatedMar 31, 2026

What is Lumacaftor and Ivacaftor used for?

ORKAMBI is indicated for the treatment of cystic fibrosis (CF) in patients aged 1 year and older who are homozygous for the F508del mutation in the CFTR gene. If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene.

Limitations of Use

The efficacy and safety of ORKAMBI have not been established in patients with CF other than those homozygous for the F508del mutation.

Lumacaftor and Ivacaftor dosage

The recommended dosage of ORKAMBI in adults and pediatric patients aged one year and older is based on patient's age and weight as described in Table 1.

Age Group | Weight | ORKAMBI Daily Dose (every 12 hours)

Morning Dose | Evening Dose

1 through 2 years | 7 kg to <9 kg | 1 packet of lumacaftor 75 mg/ivacaftor 94 mg oral granules | 1 packet of lumacaftor 75 mg/ivacaftor 94 mg oral granules

9 kg to <14 kg | 1 packet of lumacaftor 100 mg/ivacaftor 125 mg oral granules | 1 packet of lumacaftor 100 mg/ivacaftor 125 mg oral granules

≥14 kg | 1 packet of lumacaftor 150 mg/ivacaftor 188 mg oral granules | 1 packet of lumacaftor 150 mg/ivacaftor 188 mg oral granules

2 through 5 years | <14 kg | 1 packet of lumacaftor 100 mg/ivacaftor 125 mg oral granules | 1 packet of lumacaftor 100 mg/ivacaftor 125 mg oral granules

≥14 kg | 1 packet of lumacaftor 150 mg/ivacaftor 188 mg oral granules | 1 packet of lumacaftor 150 mg/ivacaftor 188 mg oral granules

6 through 11 years | - | 2 tablets of lumacaftor 100 mg/ivacaftor 125 mg(lumacaftor 200 mg/ivacaftor 250 mg per dose) | 2 tablets of lumacaftor 100 mg/ivacaftor 125 mg(lumacaftor 200 mg/ivacaftor 250 mg per dose)

12 years and older | - | 2 tablets of lumacaftor 200 mg/ivacaftor 125 mg(lumacaftor 400 mg/ivacaftor 250 mg per dose) | 2 tablets of lumacaftor 200 mg/ivacaftor 125 mg(lumacaftor 400 mg/ivacaftor 250 mg per dose)

Administration Instructions for ORKAMBI Oral Granules

The entire content of each packet of oral granules should be mixed with one teaspoon (5 mL) of age-appropriate soft food or liquid and the mixture completely consumed. Some examples of soft foods or liquids include puréed fruits or vegetables, flavored yogurt or pudding, applesauce, water, milk, breast milk, infant formula or juice. Food should be at room temperature or below. Each packet is for single use only. Once mixed, the product has been shown to be stable for one hour, and therefore should be ingested during this period.

Administration with Fat-Containing Food for ORKAMBI Tablets and Oral Granules

A fat-containing meal or snack should be consumed just before or just after dosing for all formulations. Examples of appropriate fat-containing foods include eggs, avocados, nuts, butter, peanut butter, cheese pizza, breast milk, infant formula, whole-milk dairy products (such as whole milk, cheese, and yogurt), etc.

Missed Dose

If a patient misses a dose and remembers the missed dose within 6 hours, the patient should take the dose with fat-containing food. If more than 6 hours elapsed after the recommended dosing time, the patient should skip that dose and resume the normal schedule for the following dose. A double dose should not be taken to make up for the forgotten dose . …

How to take Lumacaftor and Ivacaftor — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Advanced Liver Disease

Inform patients that worsening of liver function, including hepatic encephalopathy, in patients with advanced liver disease occurred in some patients treated with ORKAMBI. Liver function decompensation, including liver failure leading to death, has been reported in CF patients with pre-existing cirrhosis with portal hypertension while receiving ORKAMBI .

Abnormalities in Liver Function and Testing

Inform patients that abnormalities in liver function have occurred in patients treated with ORKAMBI. Blood tests to measure transaminases (ALT and AST) and bilirubin will be performed prior to initiating ORKAMBI, every 3 months during the first year of therapy, and annually thereafter. Advise patients to contact their healthcare provider if they develop symptoms consistent with hepatotoxicity .

Hypersensitivity Reactions, Including Anaphylaxis

Hypersensitivity reactions including angioedema and anaphylaxis are possible with use of ORKAMBI. …

Warnings & precautions

Do not take this medicine if: None.

Worsening of liver function, including hepatic encephalopathy, in patients with advanced liver disease has been reported. Liver function decompensation, including liver failure leading to death, has been reported in CF patients with pre-existing cirrhosis with portal hypertension while receiving ORKAMBI. Use ORKAMBI with caution in patients with advanced liver disease and only if the benefits are expected to outweigh the risks. If ORKAMBI is used in these patients, they should be closely monitored after the initiation of treatment and the dosage should be reduced .

Serious adverse reactions related to elevated transaminases have been reported in patients with CF receiving ORKAMBI. In some instances, these elevations have been associated with concomitant elevations in total serum bilirubin.

It is recommended that ALT, AST, and bilirubin be assessed prior to initiating ORKAMBI, every 3 months during the first year of treatment, and annually thereafter. For patients with a history of ALT, AST, or bilirubin elevations, more frequent monitoring should be considered. Patients who develop increased ALT, AST, or bilirubin should be closely monitored until the abnormalities resolve.

Dosing should be interrupted in patients with ALT or AST >5 × upper limit of normal (ULN) when not associated with elevated bilirubin. Dosing should also be interrupted in patients with ALT or AST elevations >3 × ULN when associated with bilirubin elevations >2 × ULN. Following resolution of transaminase elevations, consider the benefits and risks of resuming dosing .

Hypersensitivity reactions, including cases of angioedema and anaphylaxis, have been reported in the postmarketing setting . If signs or symptoms of serious hypersensitivity reactions develop during treatment, discontinue ORKAMBI and institute appropriate therapy. …

Lumacaftor and Ivacaftor side effects

The following adverse reactions are discussed in greater detail in other sections of the label:

Use in Patients with Advanced Liver Disease

Liver-related Events

Hypersensitivity Reactions, Including Anaphylaxis

Intracranial Hypertension

Neuropsychiatric Events, Including Suicidal Thoughts and Behaviors

Respiratory Events

Effect on Blood Pressure

Cataracts

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The overall safety profile of ORKAMBI is based on the pooled data from 1108 patients with CF aged 12 years and older who are homozygous for the F508del mutation in the CFTR gene and who received at least one dose of study drug in two double-blind, placebo-controlled, Phase 3 clinical trials, each with 24 weeks of treatment (Trials 1 and 2).

In addition, the following clinical trials have been conducted:

A 24-week, open-label trial (Trial 3) in 58 patients with CF aged 6 through 11 years homozygous for the F508del-CFTR mutation.

A 24-week, placebo-controlled trial (Trial 4) in 204 patients aged 6 through 11 years homozygous for the F508del-CFTR mutation.

A 24-week, open-label trial (Trial 5) in 46 patients aged 12 years and older homozygous for the F508del-CFTR mutation and with advanced lung disease (ppFEV1 <40). …

Drug interactions

Potential for Other Drugs to Affect Lumacaftor/Ivacaftor

Co-administration of lumacaftor/ivacaftor with itraconazole, a strong CYP3A inhibitor, did not impact the exposure of lumacaftor, but increased ivacaftor exposure by 4.3-fold. Due to the induction effect of lumacaftor on CYP3A, at steady-state, the net exposure of ivacaftor is not expected to exceed that when given in the absence of lumacaftor at a dose of 150 mg every 12 hours (the approved dose of ivacaftor monotherapy). Therefore, no dosage adjustment is necessary when CYP3A inhibitors are initiated in patients currently taking ORKAMBI. However, when initiating ORKAMBI in patients taking strong CYP3A inhibitors, reduce the ORKAMBI dosage as recommended for the first week of treatment to allow for the steady-state induction effect of lumacaftor. Following this period, continue with the recommended daily dose .

Examples of strong CYP3A inhibitors include:

ketoconazole, itraconazole, posaconazole, and voriconazole.

telithromycin, clarithromycin.

No dosage adjustment is recommended when used with moderate or weak CYP3A inhibitors.

Co-administration of lumacaftor/ivacaftor with rifampin, a strong CYP3A inducer, had minimal effect on the exposure of lumacaftor, but decreased ivacaftor exposure (AUC) by 57%. …

About this medicine

The active ingredients in ORKAMBI tablets are lumacaftor, which has the following chemical name: 3-[6-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-3-methylpyridin-2-yl]benzoic acid, and ivacaftor, a CFTR potentiator, which has the following chemical name: N-(2,4-di-tert-butyl-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide. The molecular formula for lumacaftor is C24H18F2N2O5 and for ivacaftor is C24H28N2O3. The molecular weights for lumacaftor and ivacaftor are 452.41 and 392.49, respectively. The structural formulas are:

Lumacaftor is a white to off-white powder that is practically insoluble in water (0.02 mg/mL). Ivacaftor is a white to off-white powder that is practically insoluble in water (<0.05 µg/mL).

ORKAMBI is available as a pink, oval-shaped, film-coated tablet for oral administration containing 200 mg of lumacaftor and 125 mg of ivacaftor. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 3fc1c40e-cfac-47a1-9e1a-61ead3570600. Read the full official label on DailyMed.